Prostate cancer: Growth of AS in the USA signals reduction in overtreatment

Nature Reviews Urology

Volumn 12, Issue 11, 2015, Pages 604-605

  Murphy, Declan G ^a   Loeb, Stacy ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER THERAPY; CONSERVATIVE TREATMENT; HUMAN; LOW RISK PATIENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; UNITED STATES; UROLOGIST; MALE; PROSTATIC NEOPLASMS; TRENDS; WATCHFUL WAITING;

HUMANS; MALE; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84947041486     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.236     Document Type: Short Survey

References (10)

1. Barocas, D. A., et al. The effect of the United States Preventive Services Task Force grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the US. J. Urol. http://dx.doi.org/10.1016/j.juro.2015.06.075.
2. Bhindi, B., et al. Impact of the, U. S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J. Urol. 193, 1519-1524 (2015).
3. Gulati, R., et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer 120, 3519-3526 (2014).
4. Cooperberg, M. R., Broering, J. M., & Carroll, P. R. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28, 1117-1123 (2010).
5. Cooperberg, M. R., & Carroll, P. R. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 314, 80-2 (2015).
6. Womble, P. R., et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur. Urol. 67, 44-50 (2015).
7. Weerakoon, M., et al. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry. BJU Int. 115 (Suppl. 5), 50-56 (2015).
8. Loeb, S., Berglund, A., & Stattin, P. Population-based study of utilization and determinants of active surveillance and watchful waiting for low-And intermediate-risk prostate cancer. J. Urol. 190, 1742-1749 (2013).
9. Loeb, S., Folkwaljon, Y., Bratt, O., Robinson, D., & Stattin, P. E. Expanding use of active surveillance: data from the National Prostate Cancer Register (NPCR) of Sweden. J. Urol. 193, e512 (2015).
10. Murphy, D. G., et al. The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int. 113, 186-188 (2014).